Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) is dated July 15, 2004. The report addresses the status of the proposed acquisition of Aventis, specifically focusing on regulatory approvals in the United States.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update regarding a merger and does not contain financial performance data.
Material Changes
The primary material event reported is the completion of the U.S. Federal Trade Commission's (FTC) Bureau of Competition and Economics review of the proposed acquisition of Aventis. The Bureau has forwarded a proposed Consent Decree to the Commission for acceptance and placement on the public record.
Guidance, Outlook, and Risks
- Regulatory Status: The transaction remains subject to the acceptance of the proposed Consent Decree by the FTC Commission.
- Offer Structure: Public offers are being made in France, the U.S., and Germany on substantially the same terms. Completion is subject to the same conditions, and the offers are intended to expire simultaneously.
- Investor Action: Investors are urged to read the Registration Statement on Form F-4, the prospectus, and the prospectus supplement regarding the revised offer for important information.
- Documentation: Additional documents regarding the transaction are being filed with the SEC and the French Autorite des marches financiers (AMF).
Key Facts for Investor Verification
- Verify the final acceptance of the FTC Consent Decree regarding the Aventis acquisition.
- Review the Registration Statement on Form F-4 (File No. 333-112314) and related prospectus supplements for revised offer terms.
- Confirm the expiration dates for the French, U.S., and German offers, which are intended to coincide.
- Check for any subsequent filings that may supersede the information contained in this Form 6-K.